The industry has pulled in $322 billion over the past six months, the fastest pace since the second half of 2008.Marketsread more
Today's rally clearly indicates that the market is happy for the moment with just a partial deal. But the Dow gave up 200 of its 500-point gain in the final half hour as...Trader Talk with Bob Pisaniread more
While Warren's ad about Facebook isn't true, the company's own policy allows politicians to make such false claims in paid advertising.Politicsread more
California's Tehachapi Pass is already home to one of the largest wind farms in the world, and now Amazon is coming, building a huge wind project in the area. How...Powering the Futureread more
Fisher was initially defiant amid the backlash in an interview with Bloomberg, in which he said he had "given a lot of talks, a lot of times, in a lot of places and said stuff...Investingread more
The Japan Meteorological Agency warned of dangerously heavy rainfall in Tokyo and surrounding regions as a powerful typhoon lashes Japan. A coastal earthquake also rattled the...Weather & Natural Disastersread more
Boeing's board removed CEO Dennis Muilenburg as chairman amid the fall out of two 737 Max crashes that killed 346 people.Aerospace & Defenseread more
Turkish forces claimed to have taken control of a key Syrian border town Saturday as their assault against Kurdish fighters in the region continued. The capture of the town...World Politicsread more
Investigators in Manhattan after examining Giuliani's efforts to undermine the American ambassador to Ukraine, Marie L. Yovanovitch, and if he broke laws in place to prevent...Politicsread more
The news comes one week after PayPal announced its withdrawal as government regulators continue to scrutinize the plans.Technologyread more
The U.S. and China agreed on a "substantial phase one" trade deal that delays tariff hikes set to kick in next week.Marketsread more
The Food and Drug Administration is threatening to take criminal action against Novartis, saying Tuesday the drugmaker used data it knew was inaccurate in its application for a $2.1 million gene therapy that was approved in May.
"On June 28, following the FDA's approval of the product, the agency was informed by AveXis Inc., the product's manufacturer, about a data manipulation issue that impacts the accuracy of certain data from product testing performed in animals submitted in the biologics license application and reviewed by the FDA," Peter Marks, director of FDA's Center for Biologics Evaluation and Research, said in a statement.
AveXis is the gene therapy subsidiary of Novartis. The FDA said the gene therapy for spinal muscular atrophy should remain on the market, even while it's still assessing the situation.
"The agency will use its full authorities to take action, if appropriate, which may include civil or criminal penalties," Marks added.
U.S.-traded shares of the Swiss drugmaker tumbled 3.6% in early afternoon trading. Biogen, which also produces a spinal muscular atrophy treatment, was up about 1%.
In May, the FDA approved Novartis' gene therapy, making it the world's most expensive drug. The therapy, Zolgensma, is a one-time treatment for spinal muscular atrophy, a muscle-wasting disease and leading genetic cause of infant mortality that affects one in every 11,000 births.
In a statement, Novartis said it continues to be "fully confident in the safety, quality and efficacy of Zolgensma.
"The FDA supports the continued marketing and use of Zolgensma for patients with spinal muscular atrophy (SMA) less than 2 years of age," the statement read. "We maintain that the totality of the evidence demonstrating the product's effectiveness and its safety profile continue to provide compelling evidence supporting an overall favorable benefit-risk profile. We remain steadfast that this important treatment remain available to pediatric patients with SMA less than 2 years of age."
The company added that, as noted by the FDA, "the data in question were a small portion of our overall submission and are limited to an older process no longer in use." According to Novartis, findings from the investigation did not indicate issues with product safety, efficacy or quality.
At the time the FDA approved the gene therapy, Acting FDA Commissioner Ned Sharpless lauded the approval, saying that it marked "another milestone in the transformational power of gene and cell therapies to treat a wide range of diseases."
In a tweet Tuesday, Sharpless said the agency relies "on truthful scientific data to make regulatory decisions, and we take the issue of data integrity very seriously."
This story is developing. Check back for updates.